针对业绩预增的原因，药明康德表示，公司持续聚焦独特的"一体化、端到端"CRDMO（合同研究、开 发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工 艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病 患。 北京商报讯（记者 丁宁）1月12日晚间，药明康德（603259）发布2025年度业绩预增公告显示，公司预 计2025年度实现营业收入约454.56亿元，同比增长约15.84%，其中持续经营业务收入同比增长约 21.4%。公司预计本期实现归属净利润约191.51亿元，同比增长约102.65%，其中包含了出售联营公司部 分股权以及剥离部分业务所获得的投资收益。 此外，本期非经常性损益项目对归属净利润的影响主要来自于出售持有的WuXi XDC Cayman Inc.部分 股权的净收益，预计约41.61亿元；以及出售所持有的上海康德弘翼医学临床研究有限公司和上海药明 津石医药科技有限公司100%股权的净收益，预计约14.34亿元。 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects significant revenue and profit growth for the fiscal year 2025, driven by its integrated CRDMO business model and increasing client demand for enabling services [1] Financial Performance - The company anticipates a revenue of approximately RMB 45.456 billion, representing a year-on-year increase of about 15.84% [1] - Expected revenue from continuing operations is projected to grow by approximately 21.40% [1] - Adjusted net profit attributable to shareholders is estimated at around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1] - Total net profit is projected to reach approximately RMB 19.151 billion, marking a year-on-year growth of about 102.65% [1] - Total profit is expected to be around RMB 23.906 billion, indicating a year-on-year increase of approximately 107.16% [1] - Basic earnings per share are anticipated to be approximately RMB 6.70, reflecting a year-on-year growth of about 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, aiming to meet the growing client demand for enabling services [1] - WuXi AppTec is committed to expanding new capabilities, building new production capacity, and continuously optimizing production processes to enhance operational efficiency [1] - The company aims to drive steady business growth while efficiently empowering clients and delivering more new and effective drugs to global patients [1]

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 正面盈利預告 本公告乃由本公司根據上海證券交易所股票上市規則的規定及香港聯合交易 所有限公司證券上市規則第13.09(2)(a)條及香港法例第571章《證券及期貨條例》 第XIVA部有關披露義務的規定，在上海證券交易所及香港聯合交易所有限 公司同步刊登。董事會謹此公告，預期本公司於截至2025年12月31日止年度 營業收入及歸屬於本公司股東的淨利潤相比2024年年度同期將錄得上升。 股東及有意投資者在買賣本公司證券時務須謹慎行事。 本公告乃由無錫藥明康德新藥開發股份有限公司（「本公司」或「公司」）根據上 海證券交易所股票上市規則的規定及香港聯合交易所有限公司證券上市規則 第13.09(2)(a)條及香港法例第571章《證券及期貨條例》第XIVA部有關披露義務 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects a net profit of 19.151 billion yuan for the year 2025, representing a year-on-year increase of approximately 103% [1] Financial Performance - The expected basic earnings per share for the period is approximately 6.70 yuan per share, reflecting a year-on-year growth of about 104.27% [1] - The increase in net profit includes gains from the sale of partial equity in an associate company and the divestiture of certain business segments [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment, continuously expanding new capabilities, building new production capacity, and optimizing production processes to enhance operational efficiency [1] Non-Recurring Gains - The impact of non-recurring gains on the net profit attributable to shareholders mainly comes from the net gain of approximately 4.161 billion yuan from the sale of part of its stake in WuXi XDCCayman Inc. [1] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around 1.434 billion yuan [1]

Core Viewpoint - WuXi AppTec expects to achieve approximately RMB 45.456 billion in revenue for the fiscal year 2025, representing a year-on-year growth of about 15.84% [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders is estimated to reach approximately RMB 19.151 billion, showing a significant year-on-year growth of about 102.65% [1] Revenue and Profit Growth - The anticipated revenue growth is primarily driven by the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - The increase in net profit is also attributed to gains from the sale of partial equity in joint ventures and the divestiture of certain business segments [1]

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 45.456 billion in 2025, representing a year-on-year growth of about 15.84% [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders is anticipated to reach approximately RMB 19.151 billion, showing a significant year-on-year growth of about 102.65% [1] Revenue and Profit Growth - The expected revenue growth is driven by the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - The increase in net profit is also attributed to gains from the sale of partial equity in joint ventures and the divestiture of certain business segments [1]

Core Viewpoint - WuXi AppTec (603259.SH) expects significant revenue and profit growth for the fiscal year 2025, driven by its integrated CRDMO business model and increasing client demand for enabling services [1] Financial Performance - The company anticipates a revenue of approximately RMB 45.456 billion, representing a year-on-year increase of about 15.84% [1] - Adjusted net profit attributable to shareholders is expected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56%, primarily impacted by exchange rate fluctuations [1] - Total net profit is expected to reach approximately RMB 19.151 billion, marking a year-on-year growth of about 102.65% [1] - The total profit for the period is projected to be around RMB 23.906 billion, indicating a year-on-year increase of approximately 107.16% [1] - Basic earnings per share are expected to be around RMB 6.70, reflecting a year-on-year growth of approximately 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, aiming to meet the growing client demand for enabling services [1] - WuXi AppTec is committed to expanding new capabilities, building new production capacity, and continuously optimizing production processes to enhance operational efficiency [1] - The company aims to drive steady business growth while efficiently empowering clients and striving to deliver more new and effective drugs to global patients [1]

药明康德公告称，预计2025年实现营业收入约454.56亿元，同比增长15.84%，其中持续经营业务收入同 比增21.40%；经调整归母净利润约149.57亿元，同比增长41.33%；扣非净利润约132.41亿元，同比增长 32.56%；归母净利润约191.51亿元，同比增长102.65%；基本每股收益约6.70元/股，同比增长 104.27%。业绩增长因公司聚焦CRDMO业务模式，且非经常性损益包括出售股权等净收益约55.95亿 元。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical sector has shown weaker performance compared to the overall market, with the biopharmaceutical sector outperforming with a 7.81% increase [1]. - The brain-computer interface (BCI) industry is experiencing significant breakthroughs and commercialization opportunities, driven by favorable policies and technological advancements [2][18]. - The AI healthcare market is projected to grow substantially, with the global market size expected to increase from USD 13.7 billion in 2022 to USD 155.3 billion by 2030, reflecting a CAGR of 35.5% [23][28]. Summary by Sections Market Performance - The overall A-share market increased by 4.09%, while the biopharmaceutical sector rose by 7.81%, indicating strong sector performance [1]. - The TTM price-to-earnings ratio for the biopharmaceutical sector is at 38.96x, which is at the 85.59th percentile of the past five years [1]. Brain-Computer Interface (BCI) - The BCI market is expected to see explosive growth due to policy support, including the "14th Five-Year Plan" and the establishment of independent billing codes for BCI devices [2][18]. - Key investment opportunities include upstream hardware suppliers, midstream companies with core patents, and downstream firms that create commercial applications in rehabilitation and industrial control [2][18]. AI in Healthcare - AI is identified as a critical application area in healthcare, with various themes such as AI in drug development, multi-omics, precision diagnostics, imaging devices, and smart healthcare being highlighted for investment [3][22]. - The launch of ChatGPTHealth by OpenAI signifies a growing trend in integrating AI with healthcare applications, enhancing patient interaction with health data [29]. Company Earnings Forecasts - Several companies in the sector have been rated as "Outperform," with projected net profits for 2024 ranging from CNY 1.4 billion to CNY 116.7 billion [4]. - Notable companies include Mindray Medical (CNY 116.7 billion), WuXi AppTec (CNY 93.5 billion), and Aier Eye Hospital (CNY 35.6 billion), all showing strong growth potential [4].

Investment Rating - The report maintains a positive outlook on innovative drugs and the related industry chain, indicating potential value revaluation for specific pharmaceutical companies [6][28]. Core Insights - The pharmaceutical sector in A-shares showed strong performance in the second week of January 2026, with the SW Pharma Bio index rising by 7.8%, outperforming the overall market [8][29]. - Key sub-sectors such as medical services (+12.3%), medical equipment (+9.4%), and chemical preparations (+7.3%) demonstrated significant growth during this period [13][29]. - Notable individual stock performances included Innovative Medical Management (+61.0%), Sanbo Hospital Management Group (+56.2%), and MeHow Medical (+56.1%) [15][29]. - The report highlights a normal premium level of 68.3% for the pharmaceutical sector relative to all A-shares as of January 9, 2026 [15][23]. Summary by Sections 1. Continued Focus on Innovative Drugs and Industry Chain - The report emphasizes the high prosperity in innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical for potential value revaluation [6][28]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of January 2026, the A-share pharmaceutical sector outperformed the market, with the SW Pharma Bio index increasing by 7.8% [8][29]. - The report ranks the pharmaceutical sector as the 5th best-performing industry among Shenwan's primary industries during this period [11][29]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare index rising by 10.3% and the biotechnology sector increasing by 11.1% [20][29]. - Conversely, the U.S. pharmaceutical sector underperformed, with the S&P Healthcare Select Sector rising by only 1.1% compared to the S&P 500's 1.6% increase [20][29].